Ran-Perindopril

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ran-Perindopril

What is Ran-Perindopril?

Ran-Perindopril is a pharmaceutical medication belonging to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It contains the active medicinal ingredient perindopril erbumine.

Mechanism of Action

This medication works by inhibiting the activity of an enzyme in the body that produces angiotensin II, a substance that causes blood vessels to tighten and narrow. By blocking the production of this enzyme, Ran-Perindopril helps blood vessels to relax and widen. This action facilitates easier blood flow throughout the body and reduces the workload on the heart.

Primary Uses

Ran-Perindopril is primarily utilized in the management of cardiovascular conditions, including:

  • Hypertension: It is used to help lower high blood pressure. Maintaining blood pressure within a target range helps reduce the long-term risk of cardiovascular complications.
  • Congestive Heart Failure: It may be used as part of a treatment regimen to help manage the symptoms and progression of heart failure, often in combination with other medications such as diuretics.
  • Reduction of Cardiovascular Risk: In individuals with stable coronary artery disease, it may be used to reduce the risk of serious cardiovascular events, such as heart attacks.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Ran-Perindopril?

Possible Side Effects and Safety Information

Adverse reactions associated with Ran-Perindopril (Perindopril) are classified by frequency and grouped according to the physiological system affected, based on official regulatory documentation.


Frequency-Classified Adverse Reactions

The most Common effects, affecting between 1% and 10% of individuals, typically include cough, headache, dizziness, fatigue, and hypotension (low blood pressure). Less Uncommon reactions may involve mood alterations, sleep disturbances, dry mouth, or itching. Rare and Very Rare events documented in regulatory sources include serious conditions like hepatic failure, agranulocytosis (severe white blood cell reduction), and pancreatitis.


Serious Safety Concerns

Regulatory labels emphasize the risk of Angioedema, which is rapid swelling of tissues including the face, tongue, and throat, posing a potential airway risk. Severe symptomatic hypotension is also documented, particularly upon initiation of therapy, which can lead to complications. The drug is contraindicated in patients with a history of ACE inhibitor-related angioedema and during the second and third trimesters of pregnancy due to risk of fetal injury.


Population and Exposure Considerations

Safety notes specify that Renal Impairment necessitates careful dosage adjustment. Hypotension is often more pronounced following the initial dose or dose escalation, a time-related safety pattern noted in regulatory texts. Additionally, there is a risk of hyperkalemia (elevated potassium levels), a safety element requiring caution, especially in patients with existing renal issues.

Overdose and Emergency Response

The official regulatory profile for Ran-Perindopril overdose is defined by the risk of excessive circulatory depression resulting from the action of the medicine. The most likely clinical manifestation of an overdose is Severe Hypotension (dangerously low blood pressure), which may be accompanied by symptoms such as dizziness, lightheadedness, or fainting (syncope). Cardiac effects such as tachycardia (fast heart rate) or bradycardia (slow heart rate) are also documented.

In susceptible individuals, the profound reduction in blood pressure may lead to severe, life-threatening outcomes. These documented complications include Acute Renal Failure, Myocardial Infarction (heart attack), or Cerebrovascular Accident (stroke), which are secondary to the inadequate blood flow to critical organs caused by excessive hypotension.

In the event of a suspected overdose, regulatory guidance mandates that you seek immediate medical attention. Emergency services must be contacted without delay if severe manifestations, such as collapse, seizure, trouble breathing, or inability to be awakened, are observed. Management is symptomatic and supportive, as no specific antidote is known. Officially described procedures include placing the individual in the supine position and administering an intravenous infusion of physiological saline to restore volume, alongside continuous monitoring of vital signs and serum electrolytes.

Therapeutic Uses of Ran-Perindopril

Quick Facts

  • Aids in managing elevated blood pressure (hypertension).
  • Supports care for symptomatic heart failure.
  • Assists in reducing cardiovascular events, such as a heart attack, in individuals with stable coronary artery disease.

What Ran-Perindopril Treats: Main Uses and Benefits

Ran-Perindopril is a prescription medication utilized in the management of specific cardiovascular conditions. The primary therapeutic domain of this medicine involves assisting in the control of high blood pressure, medically termed essential hypertension. Controlling elevated blood pressure is important to help limit the risks associated with cardiovascular and cerebrovascular health.

The medication is also prescribed to support the care of individuals diagnosed with symptomatic heart failure, a condition where the heart requires assistance to circulate blood throughout the body effectively. Furthermore, for patients with established stable coronary artery disease, Ran-Perindopril is used as an adjunctive treatment to contribute to the reduction of risk for certain cardiac events, including non-fatal heart attacks.

It is important to understand that this medication supports the treatment of these conditions and does not represent a curative intervention. Treatment using Ran-Perindopril forms part of a comprehensive strategy that may include other medications and lifestyle modifications.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Ran-Perindopril (Perindopril) is officially approved for use in adult patients for the management of essential hypertension, symptomatic heart failure, and stable coronary artery disease. Eligibility is strictly defined by government regulatory labeling, which establishes specific populations who must not use the medicine.


Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with a history of angioedema related to any ACE inhibitor or with hereditary/idiopathic angioedema. The medicine is strictly prohibited in pregnant women; official labeling requires discontinuation immediately upon detection of pregnancy. Furthermore, it is contraindicated in patients with diabetes or renal impairment concomitantly taking aliskiren, and in those taking sacubitril/valsartan.


Age and Condition Restrictions

The medicine is not recommended for pediatric patients (under 18 years of age) because its safety and efficacy have not been established in this group. Use is also not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min). For lactating/nursing mothers and patients with impaired liver function, official documentation advises caution or requires a determination to discontinue the medicine.

What should I know about interactions with other medicines?

Ran-Perindopril is subject to several formally documented interaction constraints. Co-administration with Sacubitril/Valsartan is strictly contraindicated due to the risk of angioedema and requires a mandatory 36-hour separation period between the last dose of one agent and the start of the other. The combination with Aliskiren is also prohibited in patients with diagnosed diabetes or impaired renal function. Furthermore, the use of Ran-Perindopril is contraindicated with certain extracorporeal treatments involving high-flux membranes.

Pharmacodynamic and Exposure-Altering Interactions

Official regulatory documents identify an increased risk of hyperkalemia with the concurrent use of Potassium-Sparing Diuretics, Potassium Supplements, or Potassium-Containing Salt Substitutes. The co-administration of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is documented as potentially causing renal function deterioration and diminishing the antihypertensive effect.

Ran-Perindopril affects the body's management of certain co-administered substances, notably causing a reversible increase in serum Lithium concentrations due to reduced clearance. In terms of drug-food interactions, regulatory data indicates that the ingestion of food reduces the bioavailability of the active metabolite, Perindoprilat, by approximately 35%.

For patients with renal impairment, the elimination of the active metabolite is decreased, resulting in drug accumulation. This factor, alongside the use of immunosuppressants, is noted as increasing the risk for certain hematological adverse effects.

Mechanism of Action

Ran-Perindopril is a prodrug that is hydrolyzed in vivo to its active moiety, perindoprilat. Perindoprilat acts as a competitive inhibitor of the metallopeptidase enzyme, Angiotensin-Converting Enzyme (ACE) (also known as Kinase II). This inhibition decreases the enzymatic conversion of the decapeptide angiotensin I into the octapeptide angiotensin II. Simultaneously, ACE inhibition reduces the degradation of the potent vasodilator bradykinin. The net result is a systemic and tissue-specific decrease in angiotensin II concentration and an increase in local bradykinin levels.

. Reduced angiotensin II limits the activation of the AT1 receptor, which attenuates vasoconstriction and decreases the secretion of the mineralocorticoid aldosterone from the adrenal cortex. Increased bradykinin levels promote the generation of local vasodilatory mediators such as nitric oxide (NO). These intracellular and local signaling modifications culminate in a system-level physiological consequence of decreased total peripheral resistance and reduced renal sodium and water reabsorption with concurrent potassium retention.

Dosage and Administration Information

Ran-Perindopril is administered by the oral route using a tablet formulation. The medication is typically taken once daily in the morning to align with the standard dosing schedule for chronic management. Administration involves taking the tablet before a meal (in a fasting state) to ensure optimal conversion of the prodrug to its active form.

Treatment protocols involve initiating therapy with a low starting dose followed by a process of titration, where the dosage is gradually increased over time to reach the established maintenance level. For the management of hypertension, the typical starting dose is 4 mg once daily, with maintenance doses often ranging from 4 mg to 8 mg, up to a maximum of 16 mg per day. When used for stable coronary artery disease, the regimen begins with 4 mg daily for two weeks, followed by an increase to a maintenance dose of 8 mg once daily.

Specific dose modifications are utilized for certain patient populations. Older adults (over 70) often begin treatment for stable coronary artery disease with a reduced dose of 2 mg daily. Dosing also requires adjustment for individuals with impaired kidney function, and the medication is generally not utilized below a CrCl of 30 mL/min. If a scheduled dose is missed, a patient should not take a double dose; the regular once-daily schedule should simply be resumed the following day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ran-Perindopril (Perindopril)


Evidence for Use in Managing High Blood Pressure (Essential Hypertension)

The research base for Perindopril in high blood pressure (hypertension) includes multiple Randomized Controlled Trials (RCTs). These studies were designed to examine Perindopril against an inactive substance (placebo) and against other established types of blood pressure medications. The primary focus of these trials was the measurement of blood pressure readings (systolic and diastolic numbers) over short-term to intermediate-term periods.

Studies report how blood pressure evolved in the observed populations, and findings indicate that reductions in blood pressure were measured in groups receiving Perindopril compared to those receiving a placebo. The major limitation is that while the research extensively covers short-term blood pressure control, long-term outcomes for individuals with uncomplicated hypertension are often inferred from larger trials conducted in higher-risk populations.


Evidence for Use in Symptomatic Heart Failure

Perindopril was evaluated in large-scale, long-term, placebo-controlled trials involving adults diagnosed with chronic symptomatic heart failure. Researchers focused on hard endpoints like all-cause mortality and the frequency of hospitalizations due to heart failure exacerbation. They also looked at functional measures, such as patient-reported outcomes describing perceived discomfort and the ability to perform daily functioning or activity level.

The main randomized trials described patterns related to a lower incidence of hospitalizations and mortality in the groups receiving Perindopril plus standard care, when compared to the groups receiving placebo plus standard care. However, the certainty remains low regarding the research for one specific type of heart failure: heart failure with preserved ejection fraction. The evidence is limited and often mixed.


Evidence for Use in Stable Coronary Artery Disease

Research for the use of Perindopril in individuals with established stable Coronary Artery Disease (CAD) was primarily explored using a single, large, long-term Randomized Controlled Trial (RCT). This study explored whether taking Perindopril could affect the chance of future cardiovascular events in adults who already had a history of heart issues but were otherwise stable. The research examined outcomes describing episodic or acute changes, specifically focusing on the composite of non-fatal heart attacks, cardiovascular death, and stroke over several years.

The main long-term trial described patterns of lower frequency for the composite MACE endpoint in the cohort receiving Perindopril compared to the placebo group. It remains uncertain whether this specific finding would apply to patients who are considered low-risk and who do not already have documented heart artery blockage.

Frequently Asked Questions (FAQ)

Common questions about Ran-Perindopril (FAQ)

Q: How is Ran-Perindopril different from other blood pressure drugs?

Ran-Perindopril is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. This means it works by specifically blocking the production of a hormone called Angiotensin II, leading to blood vessel relaxation. This mechanism is distinct from other classes of blood pressure medicines, such as beta-blockers, which primarily act by affecting the heart’s function.

Q: Can Ran-Perindopril affect my kidneys?

Official prescribing information emphasizes the need to monitor renal function (kidney function) during the course of treatment. The medication is generally not recommended for use in individuals with severe pre-existing kidney impairment. Combining it with certain other medicines, such as NSAIDs, is documented as potentially worsening kidney function.

Q: Can Ran-Perindopril be taken with other heart medicines?

Official documents list specific heart failure drug combinations, such as Sacubitril/Valsartan, as strictly contraindicated (must not be taken). For other common heart medicines, such as diuretics, careful monitoring or dosage adjustments may be required due to the risk of low blood pressure. Reviewing all concurrent medications with a healthcare provider is noted as important.

Q: What research is available on the use of Ran-Perindopril for stroke prevention?

In research supporting its use in stable coronary artery disease, studies have examined the occurrence of stroke as one element within a measure of major cardiovascular events. Furthermore, the general management of high blood pressure, for which the drug is indicated, is officially linked to the reduction of stroke risk.

Q: Can I take Ran-Perindopril with common cold or flu medication?

Certain ingredients commonly found in cold and flu products, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or sympathomimetic decongestants, are documented in regulatory information as having potential interactions. These interactions may impact blood pressure control or kidney function, and official guidance recommends that these combinations be used with caution.

Q: What are the common side effects that usually go away?

Regulatory patient leaflets note that some common side effects, such as headache or dizziness, are described in patient materials as having the potential to resolve as the body adjusts to the medicine within the first few weeks of therapy. However, another common effect, the dry cough, may be persistent.

Q: Are there any known issues with taking Ran-Perindopril before surgery?

Official guidance addresses the potential for severe low blood pressure (hypotension) during anesthesia if the medicine is continued before an operation. Specific clinical protocols for managing the risk often involve the temporary discontinuation of the medication by the supervising healthcare team.

Q: What is the difference between the various Ran-Perindopril strengths (e.g., 2mg vs 4mg)?

The different available strengths are used to support the mandatory processes of starting therapy with a low dose and gradually increasing the dose over time (titration). This is done to achieve the appropriate maintenance dose based on the specific condition being treated and individual factors like age or kidney function.

Q: Will I feel different right away after starting Ran-Perindopril?

According to pharmacological data, the active compound reaches its highest concentration in the body in a matter of hours after taking a dose. The maximal blood pressure lowering effect is typically measured within 6 to 10 hours. Effects like dizziness or low blood pressure may be noticeable during the initial period.

Q: How long does Ran-Perindopril take to start working?

While the initial, measurable blood pressure effect begins within hours of taking the dose, achieving the full prescribed therapeutic benefit involves a gradual process. This requires dose adjustment (titration) over several weeks or months to reach the optimal maintenance dose.

Q: Are there any long-term effects of taking Ran-Perindopril for years?

Studies show that long-term use is associated with positive outcomes, such as a lower frequency of cardiovascular events in certain populations. As with any long-term medication, regulatory documents recommend regular monitoring of blood work and physical symptoms over time.

Q: Is it okay to stop taking Ran-Perindopril if my blood pressure is better?

Official prescribing information advises that the medicine is typically intended for regular, long-term use and should be continued even if the patient feels well. Cessation of the medication is typically reserved for direction by a healthcare professional.

Q: Does drinking alcohol affect Ran-Perindopril?

Official regulatory information notes that consuming alcohol may increase the blood pressure-lowering effect of the medication. This additive effect can potentially lead to increased symptoms of dizziness, lightheadedness, or fainting.

Q: How often do I need to get blood tests while on Ran-Perindopril?

Regulatory documents recommend monitoring key biological parameters, specifically renal function and serum potassium levels, during therapy. The required frequency of these blood tests is determined by the prescribing healthcare provider based on individual patient health factors.

Q: What should I do if I get a persistent dry cough from Ran-Perindopril?

The dry cough is a common side effect of this class of medicine. Regulatory patient information advises that if the cough becomes persistent, bothersome, or prevents sleep, official guidance indicates that discussion with a healthcare provider is appropriate to explore management options or alternative treatments.

Q: Can the effectiveness of Ran-Perindopril change over time?

The medication is designed for long-term management of chronic conditions, and clinical research has shown sustained benefits regarding the reduction of cardiovascular risk over several years in relevant populations. Therapy is intended to be continued unless otherwise advised.

Q: Can I take antacids or indigestion remedies while on Ran-Perindopril?

Regulatory patient information recommends consultation with a healthcare professional regarding the use of other medicines, including indigestion remedies. Some specific components in these remedies may be advised to be taken separately from Ran-Perindopril to avoid interference.

How should Ran-Perindopril be stored and disposed of?

Storage and Disposal of Ran-Perindopril

Ran-Perindopril (perindopril) tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).


Storage Requirements

The medication must be kept in its original container and the container must remain tightly closed to protect the tablets from moisture and light. It is strictly required to store the medicine out of the sight and reach of children and to keep it away from excess heat and moisture, meaning it should not be stored in the bathroom.


Disposal

Do not dispose of unused or expired Ran-Perindopril by flushing it down a toilet or throwing it into household waste. Official instructions require returning any unwanted medicine to a pharmacist for safe disposal, which helps to protect the environment and complies with pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ran-Perindopril found in:

A-Z Index: